SCHEMBL5840858

SCHEMBL5840858

Cc1cc2ncn(C(=O)OC(C)(C)C)c2cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
TP53 P04637 1/20 0.42
KMT2A Q03164 7/20 0.42
MEN1 O00255 4/20 0.42
GFER P55789 1/20 0.41
HTT P42858 2/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
MAPT P10636 2/20 0.37
TSHR P16473 1/20 0.37
F2 P00734 1/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA3 P07451 2/20 0.37
CA4 P22748 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5840794 0.95 ALDH1A1 (0.43) ALDH1A1LMNAMAPK1NPSR1SMN1; SMN2
SCHEMBL31543097 0.80 HSP90AA1 (0.39) ALDH1A1LMNASMN1; SMN2TP53POLB
SCHEMBL31543369 0.80 HSP90AA1 (0.39) ALDH1A1LMNASMN1; SMN2TP53POLB
SCHEMBL832385 0.78 BRD4 (0.40) LMNANPSR1KMT2AMEN1GFER
SCHEMBL832377 0.78 GABRG2 (0.44) SMN1; SMN2TP53KMT2AMEN1GFER
SCHEMBL482648 0.77 NR1H2 (0.43) ALDH1A1SMN1; SMN2MAPTHSP90AA1HSP90AB1
SCHEMBL482833 0.77 NR1H2 (0.43) ALDH1A1SMN1; SMN2KMT2AMEN1GFER
SCHEMBL5840610 0.76 USP30 (0.37) ALDH1A1LMNAMAPK1NPSR1SMN1; SMN2
SCHEMBL4816124 0.75 GABRG2 (0.47) ALDH1A1SMN1; SMN2KMT2AMEN1GFER
SCHEMBL7479053 0.75 HTR6 (0.44) ALDH1A1KMT2AMEN1GFERHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ALDH1A1 3674/4885LMNA 4410/4885MAPK1 1502/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ALDH1A1 2779/4885LMNA 4320/4885MAPK1 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.